Research ArticleInfluenza

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2

See allHide authors and affiliations

Science Translational Medicine  01 Jul 2015:
Vol. 7, Issue 294, pp. 294ra105
DOI: 10.1126/scitranslmed.aab2354

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

  • RE: Ahmed et al, Sci. Transl. Med. 7, 294ra105 (2015)
    • Robbert van der Most, GSK Vaccines
    • Other Contributors:
      • Sofia Maria Buonocore, GSK Vaccines
      • Bruce Innis, GSK Vaccines

    In their recent publication in Science Translational Medicine, Ahmed et al. proposed that the increased risk of narcolepsy following vaccination with Pandemrix™ could potentially be explained by antibody cross-reactivity between the H1N1 influenza virus nucleoprotein (NP) and the human hypocretin receptor 2 (HCRT-R2) (1). Subsequent comments in Science (2) and Science Translational Medicine (3) discussed the relevance of these findings in explaining any potential links between vaccination, influenza and narcolepsy.

    The starting point for Ahmed and colleagues was the observation that very few cases of narcolepsy were reported after vaccination with Focetria™ thus prompting a search for sequence differences between the re-assortant vaccine strains used to produce Pandemrix and Focetria (seed virus strains X-179A and X-181, respectively). Where differences between X-181 and X-179A sequences were found, they searched for sequence homologies between these influenza virus sequences, and the sequences of hypocretin and hypocretin receptors 1 and 2. The bio-informatic analysis was then based on the premise that a single amino acid difference existed at position 116 of the nucleoprotein (NP) sequences in the re-assortant strains for Pandemrix and Focetria, X-179A (I) and X-181 (M), respectively. This analysis resulted in the identification of amino acid similarity between the influenza A(H1N1)pdm09 virus nucleoprotein (NP) (YDKEEIRRIWR, defined as the mimicry sequence) and...

    Show More
    Competing Interests: All authors are employees of the GSK group of companies. Robbert van der Most and Bruce Innis own shares in GSK and are listed as inventors on patents owned by GSK
    Attachments

Navigate This Article